First use of cenerimod, a selective S1P<sub>1</sub> receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study.

导出 LinkOut

翻译打印收藏纠错

作者： Viktoria,Hermann ^[1] ; Anastas,Batalov ^[2] ; Svetlana,Smakotina ^[3] ; Pierre-Eric,Juif ^[1] ; Peter,Cornelisse ^[1]

作者单位： Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland. ^[1] Rheumatology Department, Medical University of Plovdiv, Plovdiv, Bulgaria. ^[2] Kemerovo Regional Clinical Hospital, Kemerovo, Russia. ^[3]

关键词 S1P1 cenerimod phase II sphingosine-1-phosphate receptor systemic lupus erythematosus

DOI 10.1136/lupus-2019-000354

PMID 31798918

发布时间 2022-04-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Lupus science & medicine

2019年6卷1期

e000354页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

First use of cenerimod, a selective S1P<sub>1</sub> receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study.

Lupus science & medicine

相似文献

Lupus science & medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

First use of cenerimod, a selective S1P<sub>1</sub> receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study.

Lupus science & medicine

相似文献

Lupus science & medicine

相关期刊

检索历史清除